Elena Busch
Overview
Explore the profile of Elena Busch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
99
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sandherr M, Stemler J, Schalk E, Hattenhauer T, Hentrich M, Hertenstein B, et al.
Lancet Reg Health Eur
. 2025 Feb;
51:101214.
PMID: 39973942
Febrile Neutropenia is an emergency in the treatment of cancer patients. It requires prompt and evidence-based clinical and antimicrobial management. The implementation of standard operating procedures (SOP) across hospitals and...
2.
Giesen N, Busch E, Schalk E, Beutel G, Ruthrich M, Hentrich M, et al.
Eur J Cancer
. 2023 Jan;
181:102-118.
PMID: 36652889
The novel coronavirus SARS-CoV-2 and the associated infectious disease COVID-19 pose a significant challenge to healthcare systems worldwide. Patients with cancer have been identified as a high-risk population for severe...
3.
Witt J, Haupt S, Ahadova A, Bohaumilitzky L, Fuchs V, Ballhausen A, et al.
HLA
. 2022 Oct;
101(1):24-33.
PMID: 36251018
The HLA system represents a central component of the antigen presentation machinery. As every patient possesses a defined set of HLA molecules, only certain antigens can be presented on the...
4.
Apostolidis L, Lang K, Sisic L, Busch E, Ahadova A, Wullenkord R, et al.
J Cancer Res Clin Oncol
. 2022 Apr;
149(4):1373-1382.
PMID: 35441345
Purpose: Perioperative systemic treatment has significantly improved the outcome in locally advanced esophagogastric cancer. However, still the majority of patients relapse and die. Data on the optimal treatment after relapse...
5.
Bohaumilitzky L, Kluck K, Huneburg R, Gallon R, Nattermann J, Kirchner M, et al.
Gastroenterology
. 2021 Dec;
162(3):907-919.e10.
PMID: 34863788
Background & Aims: Owing to the high load of immunogenic frameshift neoantigens, tumors arising in individuals with Lynch syndrome (LS), the most common inherited colorectal cancer (CRC) syndrome, are characterized...
6.
Busch E, Ahadova A, Kosmalla K, Bohaumilitzky L, Pfuderer P, Ballhausen A, et al.
Front Oncol
. 2021 Jun;
11:669774.
PMID: 34168989
Immune checkpoint blockade (ICB) shows remarkable clinical effects in patients with metastatic microsatellite-unstable (MSI) cancer. However, markers identifying potential non-responders are missing. We examined the prevalence of ( mutations, a...
7.
Busch E, Werft W, Bougatf N, Hackert T, Jager D, Springfeld C, et al.
Pancreas
. 2021 Apr;
50(3):300-305.
PMID: 33835959
Objectives: Acinar cell carcinoma of the pancreas (pACC) forms a rare subgroup of pancreatic tumors. We report on our institutional experience with systemic first- and further-line therapy in patients with...
8.
Busch E, Kreutzfeldt S, Agaimy A, Mechtersheimer G, Horak P, Brors B, et al.
Cold Spring Harb Mol Case Stud
. 2020 Aug;
6(4).
PMID: 32843432
Pancreatic acinar cell carcinoma (PAC) is a rare disease with a poor prognosis. Treatment options for metastatic PAC are limited and often follow chemotherapeutic regimens for pancreatic ductal adenocarcinoma. Although...
9.
Busch E, Kubon K, Mayer J, Pidelaserra-Marti G, Albert J, Hoyler B, et al.
Viruses
. 2020 Feb;
12(2).
PMID: 32098134
Priming and activation of CD8 T cell responses is crucial to achieve anti-viral and anti-tumor immunity. Live attenuated measles vaccine strains have been used successfully for immunization for decades and...
10.
Albrecht T, Rausch M, Roessler S, Geissler V, Albrecht M, Halske C, et al.
Virchows Arch
. 2019 Dec;
476(6):871-880.
PMID: 31838585
Gallbladder carcinoma (GBC) is an aggressive type of cancer with a dismal prognosis. Recent case reports have highlighted the human epidermal growth factor receptor 2 (HER2) as a promising target...